Taro Pharmaceutical Industries (NYSE:TARO) issued its earnings results on Thursday. The company reported $1.72 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.96 by ($0.24), Fidelity Earnings reports. The business had revenue of $161.30 million for the quarter, compared to the consensus estimate of $169.80 million. Taro Pharmaceutical Industries had a return on equity of 13.44% and a net margin of 42.06%.
NYSE:TARO traded up $2.91 during trading hours on Friday, reaching $86.00. 59,243 shares of the company’s stock were exchanged, compared to its average volume of 40,337. The stock has a market cap of $3.12 billion, a P/E ratio of 11.89 and a beta of 0.48. Taro Pharmaceutical Industries has a 12 month low of $76.93 and a 12 month high of $110.92. The stock has a 50-day moving average price of $83.25.
A number of analysts recently weighed in on TARO shares. Zacks Investment Research cut shares of Taro Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a report on Thursday, June 13th. TheStreet cut shares of Taro Pharmaceutical Industries from a “b-” rating to a “c” rating in a report on Thursday, May 23rd. Finally, ValuEngine cut shares of Taro Pharmaceutical Industries from a “hold” rating to a “sell” rating in a report on Thursday, May 23rd.
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.
Recommended Story: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.